ViiV reports new phase IIb/III data for cabotegravir in HIV pre-exposure prophyalxis

In the HPTN 083 study, cabotegravir given every 2 months had a lower HIV incidence rate than emtricitabine/tenofovir disproxil given once daily (0.41% vs 1.22% at final analysis). Company highlights intention to file for regulatory approval.

Source:

PharmaTimes